223 related articles for article (PubMed ID: 28371641)
1. Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer's disease.
Li Q; Yang H; Chen Y; Sun H
Eur J Med Chem; 2017 May; 132():294-309. PubMed ID: 28371641
[TBL] [Abstract][Full Text] [Related]
2. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase.
Greig NH; Utsuki T; Yu Q; Zhu X; Holloway HW; Perry T; Lee B; Ingram DK; Lahiri DK
Curr Med Res Opin; 2001; 17(3):159-65. PubMed ID: 11900310
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Butyrylcholinesterase with Fluorobenzylcymserine, An Experimental Alzheimer's Drug Candidate: Validation of Enzoinformatics Results by Classical and Innovative Enzyme Kinetic Analyses.
Kamal MA; Shakil S; Nawaz MS; Yu QS; Tweedie D; Tan Y; Qu X; Greig NH
CNS Neurol Disord Drug Targets; 2017; 16(7):820-827. PubMed ID: 28176640
[TBL] [Abstract][Full Text] [Related]
4. Discovery of Novel Pyrazolopyrimidinone Derivatives as Phosphodiesterase 9A Inhibitors Capable of Inhibiting Butyrylcholinesterase for Treatment of Alzheimer's Disease.
Yu YF; Huang YD; Zhang C; Wu XN; Zhou Q; Wu D; Wu Y; Luo HB
ACS Chem Neurosci; 2017 Nov; 8(11):2522-2534. PubMed ID: 28783948
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease?
Giacobini E
Drugs Aging; 2001; 18(12):891-8. PubMed ID: 11888344
[TBL] [Abstract][Full Text] [Related]
6. A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.
Andrisano V; Naldi M; De Simone A; Bartolini M
Expert Opin Ther Pat; 2018 Jun; 28(6):455-465. PubMed ID: 29757691
[TBL] [Abstract][Full Text] [Related]
7. Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental Alzheimer therapeutic, dihydrobenzodioxepine cymserine.
Kamal MA; Klein P; Luo W; Li Y; Holloway HW; Tweedie D; Greig NH
Neurochem Res; 2008 May; 33(5):745-53. PubMed ID: 17985237
[TBL] [Abstract][Full Text] [Related]
8. Cholinesterases: new roles in brain function and in Alzheimer's disease.
Giacobini E
Neurochem Res; 2003 Apr; 28(3-4):515-22. PubMed ID: 12675140
[TBL] [Abstract][Full Text] [Related]
9. Targeting acetylcholinesterase and butyrylcholinesterase in dementia.
Lane RM; Potkin SG; Enz A
Int J Neuropsychopharmacol; 2006 Feb; 9(1):101-24. PubMed ID: 16083515
[TBL] [Abstract][Full Text] [Related]
10. Butyrylcholinesterase: an important new target in Alzheimer's disease therapy.
Greig NH; Lahiri DK; Sambamurti K
Int Psychogeriatr; 2002; 14 Suppl 1():77-91. PubMed ID: 12636181
[TBL] [Abstract][Full Text] [Related]
11. Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus.
Mushtaq G; Greig NH; Khan JA; Kamal MA
CNS Neurol Disord Drug Targets; 2014; 13(8):1432-9. PubMed ID: 25345511
[TBL] [Abstract][Full Text] [Related]
12. Highly selective inhibition of butyrylcholinesterase by a novel melatonin-tacrine heterodimers.
Zawadzka A; Lozińska I; Molęda Z; Panasiewicz M; Czarnocki Z
J Pineal Res; 2013 May; 54(4):435-41. PubMed ID: 24325732
[TBL] [Abstract][Full Text] [Related]
13. Cholinesterase inhibition in Alzheimer's disease: is specificity the answer?
Macdonald IR; Rockwood K; Martin E; Darvesh S
J Alzheimers Dis; 2014; 42(2):379-84. PubMed ID: 24898642
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of human cholinesterases by drugs used to treat Alzheimer disease.
Darvesh S; Walsh R; Kumar R; Caines A; Roberts S; Magee D; Rockwood K; Martin E
Alzheimer Dis Assoc Disord; 2003; 17(2):117-26. PubMed ID: 12794390
[TBL] [Abstract][Full Text] [Related]
15. Kinetic analysis of the inhibition of human butyrylcholinesterase with cymserine.
Kamal MA; Al-Jafari AA; Yu QS; Greig NH
Biochim Biophys Acta; 2006 Feb; 1760(2):200-6. PubMed ID: 16309845
[TBL] [Abstract][Full Text] [Related]
16. Cholinesterase inhibitors modify the activity of intrinsic cardiac neurons.
Darvesh S; Arora RC; Martin E; Magee D; Hopkins DA; Armour JA
Exp Neurol; 2004 Aug; 188(2):461-70. PubMed ID: 15246845
[TBL] [Abstract][Full Text] [Related]
17. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition.
Ballard CG
Eur Neurol; 2002; 47(1):64-70. PubMed ID: 11803198
[TBL] [Abstract][Full Text] [Related]
18. In vivo butyrylcholinesterase activity is not increased in Alzheimer's disease synapses.
Kuhl DE; Koeppe RA; Snyder SE; Minoshima S; Frey KA; Kilbourn MR
Ann Neurol; 2006 Jan; 59(1):13-20. PubMed ID: 16278840
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and evaluation of novel ferulic acid-O-alkylamine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
Sang Z; Pan W; Wang K; Ma Q; Yu L; Yang Y; Bai P; Leng C; Xu Q; Li X; Tan Z; Liu W
Eur J Med Chem; 2017 Apr; 130():379-392. PubMed ID: 28279845
[TBL] [Abstract][Full Text] [Related]
20. Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine.
Darvesh S; McDonald RS; Darvesh KV; Mataija D; Conrad S; Gomez G; Walsh R; Martin E
Bioorg Med Chem; 2007 Oct; 15(19):6367-78. PubMed ID: 17681768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]